Immunolocalization of Influenza A Virus and Markers of Inflammation in the Human Parkinson’s Disease Brain by Rohn, Troy T. & Catlin, Lindsey W.
Boise State University
ScholarWorks
Biology Faculty Publications and Presentations Department of Biological Sciences
5-31-2011
Immunolocalization of Influenza A Virus and
Markers of Inflammation in the Human Parkinson’s
Disease Brain
Troy T. Rohn
Boise State University
Lindsey W. Catlin
Boise State University
This document was originally published by PLOS ONE (Public Library of Science) in PLOS ONE. This work is provided under a Creative Commons
Attribution-NonCommercial-ShareAlike 3.0 license. Details regarding the use of this work can be found at: http://creativecommons.org/licenses/by-
nc-sa/3.0/legalcode. DOI: 10.1371/journal.pone.0020495
Immunolocalization of Influenza A Virus and Markers of
Inflammation in the Human Parkinson’s Disease Brain
Troy T. Rohn*, Lindsey W. Catlin
Department of Biology, Boise State University, Boise, Idaho, United States of America
Abstract
Although much is known regarding the molecular mechanisms leading to neuronal cell loss in Parkinson’s disease (PD), the
initiating event has not been identified. Prevailing theories including a chemical insult or infectious agent have been
postulated as possible triggers, leading to neuroinflammation. We present immunohistochemical data indicating the
presence of influenza A virus within the substantia nigra pars compacta (SNpc) from postmortem PD brain sections.
Influenza A virus labeling was identified within neuromelanin granules as well as on tissue macrophages in the SNpc.
Further supporting a role for neuroinflammation in PD was the identification of T-lymphocytes that colocalized with an
antibody to caspase-cleaved Beclin-1 within the SNpc. The presence of influenza A virus together with macrophages and T-
lymphocytes may contribute to the neuroinflammation associated with this disease.
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Introduction
Parkinson’s disease (PD) is progressive neurodegenerative
disorder characterized by extrapyramidal movement disorders
that manifest as rigidity, resting tremor and postural instability [1].
Neuronal cell loss occurs in the substantia nigra pars compacta
(SNpc) and is associated with the presence of Lewy body inclusions
that are comprised principally of aggregated alpha-synuclein [2].
Although the molecular steps leading to alpha-synuclein aggrega-
tion and neuronal cell loss are well delineated in PD, the initiating
trigger to these events remains unknown. Two prevailing theories
involving a chemical insult or infectious agent have emerged as the
leading candidates for serving as external triggers for initiating the
pathology underlying idiopathic PD. A viral etiology for PD is
based largely on epidemiological studies indicating a possible
coincidence of PD with influenza flu pandemics, most notably the
1918–1919 ‘‘Spanish’’ influenza outbreak [3]. In addition, reports
of clusters in PD have also correlated viral agents as initiators of
parkinsonism [4,5].
Experimental evidence from animal models has also supported
a possible role of viral agents as participating in the initiating
events underlying PD. For example, intracerebral injection of a
neurovirulent strain of influenza A virus into mice indicated a
preferential localization of the virus within the substantia nigra [6].
More recently, a study by Jang et. al. demonstrated the infection of
mice with the H5N1 avian influenza virus resulted in CNS
infiltration, activation of microglia and alpha-synuclein phosphor-
ylation and aggregation that persisted long after the resolution of
the infection [7].
Despite these reports correlating a viral infection as a triggering
mechanism in PD, little direct evidence exists for the presence of
influenza A virus in PD brains. In the current study, we now report
immunohistochemical evidence for influenza A viral particles in
the human PD brain. The majority of labeling we observed for
influenza A was found on macrophages located in the substantia
nigra. In addition, we also provide evidence of other immune cell
mediators, T-lymphocytes, present in the human PD brain. Our
results suggest the localization of influenza A virus within the
substantia nigra of PD cases, along with immune cells that together
may contribute to the neuroinflammation associated with this
disease.
Results
Case demographics for PD cases are presented in Table S1 and
age at death was not significantly different between PD (mean,
74.3611.3), DLB (mean, 76.764.04) and controls (mean,
73.966.81). Representative pathology in PD cases including the
presence of Lewy bodies and neurites, gliosis, and loss of
dopaminergic neurons is depicted in Figure S1. The initial goal
of our study was to examine whether the autophagic protein,
Beclin-1, is caspase-cleaved in the PD brain. The Beclin-1 protein
is essential for the proper execution of autophagy, a process that
regulates the turnover of cellular constituents and evidence
supports this vital function may be disrupted in PD [8,9]. Previous
studies have supported a loss of function of Beclin-1 due to
proteolytic cleavage by caspases [10]. PD cases were analyzed for
the presence of caspase-cleaved Beclin-1 following application of a
site-directed caspase-cleavage antibody. We had previously used
this antibody (herein termed the Beclin caspase-cleavage product
(CCP) antibody) to demonstrate the caspase-cleavage of Beclin-1
within degenerating astrocytes and tangles of the Alzheimer’s
disease (AD) brain [11]. The BeclinCCP antibody is specific for
the caspase-cleaved fragment of Beclin-1 in situ [11]. Surprisingly,
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the application of the BeclinCCP antibody in either PD or
dementia with Lewy body (DLB) cases revealed labeling of
numerous, small cells (,10 mm), throughout the SN (Fig. 1).
Labeling was also observed in Lewy bodies (Fig. 1A), degenerating
astrocytes (Fig. 2B), and apparent oligodendrocytes (Fig. 1E).
There was a significant increase in the number of BeclinCCP-
labeled cells as compared to age-matched controls (Fig. 1F).
Because the BeclinCCP antibody is a marker for caspase
activation [11], we next determined the extent of co-localization
of this antibody with TUNEL, a marker for apoptosis. In this
regard, co-localization experiments demonstrated that 85% of
TUNEL-positive cells co-localized with the BeclinCCP antibody
(p= 1.3861025,6S.E.M.), supporting the idea that these cells were
undergoing apoptosis (Fig. 2).
Due to the pattern of labeling of the BeclinCCP antibody in SN
white matter (Fig. 1E), it was predicted that labeled cells were
oligodendrocytes. We observed staining of cells of similar size and
morphology as compared to BeclinCCP staining following
application of an oligodendrocyte antibody, anti-Olig1 in PD
cases. Thus, single-labeling experiments with anti-Oligo1 indicat-
ed labeling of oligodendrocytes exhibiting shrunken cells bodies in
PD cases, indicative of cells undergoing apoptosis (Fig. 3B),
whereas in age-matched control cases, labeling of well-defined
oligodendrocytes was observed (Fig. 3A). That the BeclinCCP
antibody was labeling oligodendrocytes was confirmed following
co-localization immunofluorescence experiments utilizing anti-
Olig1 and BeclinCCP (Fig. 3C–E). Under these experimental
conditions, quantitative analysis demonstrated that 87% of anti-
Oligo1-positive cells co-localized with the BeclinCCP antibody
(p = 1.4661026, 6S.E.M.) (Fig. 3F).
Single labeling experiments with the anti-oligodendrocyte
antibody revealed little labeling of oligodendrocytes within the
SNpc (Figure S2). Therefore, we hypothesized that an additional
cell type was being labeled with the BeclinCCP antibody in this
region. Based on the size and morphology of the cells labeled, we
performed co-localization experiments with BeclinCCP and anti-
CD3, a marker for T-lymphocytes. Co-localization of these two
antibodies using bright field microscopy was evident within the
SNpc in all PD cases examined (Fig. 4A), which was largely absent
in age-matched control cases (Fig. 4B). Due to the lack of color
separation using bright-field microscopy, additional co-localization
experiments were undertaken using immunofluorescence (Fig. 4C–
E). For immunofluorescence experiments, of those cells that were
CD3-positive, 78% of these cells also were labeled with the
BeclinCCP antibody (p = 7.0861025, 6S.E.M.) (Fig. 4H). The
presence of caspase-cleaved Beclin-1 within T-lymphocytes would
suggest caspase activation, a general feature of T-lymphocytes
undergoing activation [12]. The presence of CD3-positive cells
itself is not indicative of neuroinflammation, therefore, further
experiments were performed to assess the type of T-lymphocytes
using CD4 and CD8 antibodies. We detected the presence of both
CD4+ and CD8+ T-lymphocytes in PD cases, and the staining
profile was similar for both antibodies (Fig. 4F and G). In addition,
staining of cells was often in areas of depigmentation (Fig. 4G),
which may be indicative of neuroinflammation [13]. These results
suggest the presence of both helper and cytotoxic T-lymphocytes
in the SNpc of the PD brain, supporting previous studies
[14,15,16].
Because T-lymphocytes are known to respond to viral antigens
and due to the long-standing idea that the triggering mechanism in
PD involves an infectious agent [6], we examined PD cases
utilizing an influenza A virus antibody known to detect numerous
strains of the virus (Prosci, catalogue #35-481). We observed
labeling on apparent macrophages in both PD (Fig. 5A–C) and
control cases (Fig. 5D), although there was a significant increase
(p = 0.01) in labeled macrophages of PD cases (Fig. 5E). Evidence
for influenza A labeling was observed in all five PD cases examined
and staining was absent in the presence of secondary antibody only
(Fig. 5O). In addition, we examined PD cases for the presence of
influenza B viral proteins, a virus not linked to PD and more
commonly found in children than the elderly [17]. We were
unable to detect any influenza B labeling in PD cases (Fig. 5P),
suggesting a lack of this infectious agent in the PD brain.
Double label immunofluorescence experiments confirmed the
co-localization of influenza A on macrophages (CD206 antibody)
(Fig. 5F–K). We also observed punctate labeling of the influenza A
virus antibody within neuromelanin structures (Fig. 5B). Co-
localization experiments demonstrated that 80% of Macrophage-
positive cells co-localized with the influenza A virus antibody
(p = 4.5561026,6S.E.M.) (Fig. 5Q). These results were confirmed
using additional, distinct antibodies to macrophages (CD14) and
influenza A virus (ProSci #35-483) (Fig. 5L–N). Similar results
were also observed in DLB cases (Figure S3).
In a final set of experiments, triple-labeling experiments were
undertaken in representative PD cases to determine the localiza-
tion of influenza A virus, BeclinCCP, and CD8+ T-lymphocytes
(Fig. 6). The overlap image for the three antibodies indicated the
presence of an apparent macrophage labeled with both anti-
influenza A and BeclinCCP surrounded by CD8+ T-lymphocytes
(Fig. 6D). In addition, co-localization of the influenza A virus
within CD8+ T-lymphocytes was evident, and many of these cells
tended to cluster around the macrophage (Fig. 6D). These results
are suggestive of a possible interaction between cytotoxic T-
lymphocytes and macrophages.
Discussion
Several important findings can be drawn from the current
immunohistochemical study in PD. The first important finding of
the current study was the identification of apoptotic oligodendro-
cytes labeled by the Beclin-1 caspase-cleavage product antibody
(BeclinCCP) in the white matter of the SN of PD and DLB cases.
Many of the oligodendrocytes labeled with the BeclinCCP
antibody displayed hallmark features of apoptosis including
fragmentation of processes and shrunken cell bodies. Because
the critical role oligodendrocytes play in myelination of axons in
the CNS, the degeneration of oligodendrocytes may contribute to
the extrapyramidal symptoms associated with PD.
A second finding was the presence of T-lymphocytes in the PD
brain. The infiltration of T-lymphocytes, in an attempt to mitigate
a viral infection, may help spare neuronal loss in PD. On the other
hand, emerging data implicates inflammatory processes in the
contribution of the pathophysiology underlying PD [18]. In this
regard, several studies have identified the presence of T-
lymphocytes within the SNpc in either the human PD brain or
in animal models [14,15,16]. Our data indicated the presence of
both helper and cytotoxic T-lymphocytes in PD cases, suggesting a
possible CNS infiltration of peripheral immune cells. Therefore,
our data supports a growing body of research suggesting that
adaptive immune systems may play a critical role in the
neurodegeneration associated with PD disease (for recent reviews
see [19,20]). In support of this is a recent study by Brochard et al.
who reported that CD4+ T-lymphocytes are cytotoxic in a mouse
model of PD and that invading CD4+ T-lymphocytes contributes
to dopamine neurodegeneration through Fas/FasL pathway [15].
A third finding of the current study was the presence of
influenza A viral proteins within the SNpc, which supports the
epidemiological data that has linked this virus to PD [3,4,5]. We
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Figure 1. Caspase-cleaved Beclin-1 in Parkinson’s and dementia with Lewy body disease. (A–D): High (A and B) and low magnification (C
and D), of representative single-labeling (blue) from a Parkinson’s cases utilizing the BeclinCCP antibody illustrating staining of numerous small cells
(,10 mm) in the SNpc (arrows, Fig. 1A) along with the staining of a single Lewy body (arrowhead, Fig. 1A). Comparative staining in representative
age-matched control cases showing a general lack of staining with the BeclinCCP antibody (B and D). Brown structures (A–D) represent neuromelanin
(asterisks), typical of neurons in the SNpc. (E): Representative labeling in a DLB case illustrating the ‘‘pearls-on-a-string’’ labeling with BeclinCCP in
white matter within the SN (E, arrowheads). (F): Quantification of the number of BeclinCCP-positive cells within the SNpc for age-matched control
cases (blue bar), PD cases, (red bar) and DLB cases (green bar). Results indicated a significant increase in the number of BeclinCCP-positive cells in
both PD and DLB over control cases. Data represent the average (6S.E.M.) of three different fields taken with a 406 objective from five different
cases. NS =no significant difference between PD and DLB cases (p = 0.331). *PD indicates significant difference between PD and control cases
(p = 0.0005), and *DLB indicates significant difference between DLB and control cases (p = 0.0001). Scale bars are 10 mm in A, B, and E and 50 mm in C
and D.
doi:10.1371/journal.pone.0020495.g001
Identification of Influenza A in Parkinson’s
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20495
found the presence of influenza A labeling in all seven PD and five
DLB cases examined. An important caveat of the current student
is the relatively small sample size for data analysis. It is possible
that we coincidently chose five DLB and seven PD cases that were
positive for influenza A viral proteins. It should be noted that
immunohistochemical reports have been published that were
negative for presence of influenza A viral particles or nucleic acids
in the PD brain [21,22]. However, these studies, like ours, also
consisted of a relatively small sample size of PD cases. Thus, future
studies should be directed at testing for the presence of influenza A
viral proteins utilizing a larger cohort to definitively document the
presence or absence of this virus in the PD brain. Another
important caveat of the present study is our findings do not prove
influenza A virus causes PD, but is only present in the PD brain. It
is possible that the cases we examined had seasonal influenza A
virus infection shortly before they died, and the virus had no
bearing on the course of the disease. The available clinical
information on these patients was limiting, however, it is
noteworthy that out of 7 PD cases, only one case could have
possibly had an influenza A viral infection as the cause of death
was pneumonia (Table S1).
Of particular interest was the finding that the majority of influenza
A viral labeling was found on macrophages. Macrophages play a
vital role in the immune system by phagocytosing, processing and
presenting foreign antigens on their cell surface [23]. Macrophages
are also known to stimulate T-lymphocytes and other immune cells
to respond to pathogens [23]. We also identified punctate influenza
A viral protein labeling within neuromelanin structures. In some
cases, macrophages could be seen extending pseudopods around
these structures, suggesting a role of macrophages in the clearance of
this material. Previous studies have supported the hypothesis that
influenza A viruses are neurotropic, i.e., they can travel into the
Figure 2. Co-localization of the BeclinCCP antibody with TUNEL labeling, a marker for apoptosis. (A and B): Representative bright-field
double-labeling utilizing the BeclinCCP antibody (blue) and TUNEL (DAB, brown) revealed the co-localization within small cells (arrows, A) and within
a degenerating astrocyte (B) in SNpc of representative Parkinson’s cases. (D–I): Representative immunofluorescence double-labeling within the SN
utilizing BeclinCCP (red) and TUNEL (green) in a representative PD case (D–F) or DLB (G–I). Panel G illustrates the staining of a degenerating astrocyte
that co-localized with TUNEL (Panel I). (C): Panel C depicts quantitative immunofluorescence analysis indicating that approximately 85% of TUNEL-
positive cells co-localized with the BeclinCCP antibody (p = 1.3861025). Scale bars are 10 mm.
doi:10.1371/journal.pone.0020495.g002
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nervous system following systemic infection where they preferentially
localize to the substantia nigra [6]. It is interesting to speculate on
whether influenza A viruses somehow hone in and take resident in
neurons containing neuromelanin. This in turn could lead to the
attraction, interaction, and finally activation of macrophages and
T-lymphocytes. In support of this idea were results following triple-
labeling experiments that indicated a possible interaction between
influenza A virus-macrophages and cytotoxic T-lymphocytes (Fig. 6).
Because macrophages are known to function as antigen-presenting
cells that can stimulate cytotoxic T-lymphocytes, these results suggest
a possible mechanism for the neuroinflammation associated with
PD [24].
Although neuroinflammation is one outcome following activa-
tion of the immune system in the CNS, an equally impor-
tant alternative are immune cells such as macrophages and
T-lymphocytes are serving a neuroprotective role [25]. This
apparent paradox underscores the delicate balance between either
pathogenic or repair processes, which can be triggered by the
immune response. For example, there is evidence indicating that
the immune response is beneficial rather than damaging after
brain damage. Thus, studies from Schwartz and colleagues suggest
that T-lymphocytes can elicit CNS maintenance by releasing
neuroprotective molecules such as BDNF in areas of brain injury
or provide helpful signals to resident cells, such as microglia and
astrocytes, which protect and promote the recovery of the brain
[26]. In addition, macrophages may clear debris after myelin
damage and when this is impeded, delayed regeneration occurs
[27]. Finally, results utilizing an animal model of chronic
neurodegeneration demonstrated that the presence of CD4+
T-lymphocytes provides supportive neuroprotection by modulat-
ing the trophic/cytotoxic balance of glia within the CNS [28].
Collectively, these studies emphasize that autoimmune responses
Figure 3. Degenerating oligodendrocytes co-localize with caspase-cleaved Beclin-1 in PD. (A and B): Representative labeling in control
or PD cases utilizing mAB anti-Olig1 indicated staining of well-defined, healthy oligodendrocytes in age-matched control cases (A), as compared to
PD cases where labeling was identified on oligodendrocytes exhibiting shrunken cell bodies (B). (C–E): Immunofluorescence double labeling in a
representative PD case indicated the co-localization of the BeclinCCP antibody (red, C) with anti-Olig1 (green, D). Panel E displays the overlap image
for both antibodies indicating the labeling of the BeclinCCP antibody within degenerating oligodendrocytes (yellow, E). F): Panel F depicts
quantitative analysis indicating that approximately 87% of anti-Olig1-positive cells co-localized with the BeclinCCP antibody (p = 1.4661026). All scale
bars are 10 mm.
doi:10.1371/journal.pone.0020495.g003
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Figure 4. Caspase-cleaved Beclin-1 within T-lymphocytes in the PD brain. (A and B): Bright-field double labeling in the SNpc of a
representative PD case (A) or control (B) illustrating co-localization of the BeclinCCP antibody (blue) with mAB CD3, a marker for T-lymphocytes
(brown). Note the size and co-localization of both markers in cells (arrowheads, A), and in addition the single labeling of BeclinCCP within an apparent
Identification of Influenza A in Parkinson’s
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in the CNS are not always destructive but, instead, are crucial for
repair and regeneration.
Even taking into consideration that the immune system can
serve a vital protective role in a number of acute and chronic
neurodegenerative diseases, the overwhelming body of evidence
suggest a role of neuroinflammation as a critical step underlying
the pathological disease mechanisms associated with PD [24].
Because of this, and based on our present findings, one possible
preventative mechanism to attenuate the progression of PD would
be annual vaccinations against the influenza A virus. It is
noteworthy, that the centers for disease control (CDC) currently
recommends annual vaccinations against influenza A in all
individuals over the age of 65 [29]. Although our results show
the presence of influenza A viral proteins in the SN of the PD
brain, our data do not answer directly the question as to whether
the observed PD pathology is dependent on influenza A viral
infection. It is possible that our small study cohort was infected
shortly before death and that the viral infection on a single
occasion was independent to the neuroinflammation and pathol-
ogy associated with PD. It is not possible to draw such conclusions
from immunohistochemical analysis using postmortem brain
sections from affected individuals. However, animal models of
PD do support a causal relationship between viral infection and
pathology in PD. For example, a recent study by Jang et al.
demonstrated the systemic infection of mice with the H5N1
influenza virus led to CNS penetration, microglia activation,
alpha-synuclein phosphorylation and aggregation, and loss of
dopaminergic neurons in the SNpc [7]. That the adaptive immune
system can contribute directly to neurodegeneration in PD was
shown in a mouse model of PD where the authors demonstrated
that dopaminergic cell death was markedly attenuated in the
absence of mature T-lymphocytes [15]. Taken together, these data
support a model by which, perhaps due to a low-grade chronic
viral infection in the area of the SN leads to the infiltration of
immune cells including T-lymphocytes and macrophages. These
immune cells may have a primary purpose of eradicating the
infection, but in the process also lead to the activation of resident
microglia and astrocytes which in turn damage neurons by
‘‘friendly’’ fire. The potential arsenal released by T-lymphocytes
and macrophages that may contribute to neuroinflammation
include cytokine IL-17, granzyme B, TNFa and various free
radicals, all which may contribute to dopaminergic neuronal death
[20]. Collectively, our data support the role of neuroinflammation
as an underlying feature of PD and suggest that both annual
vaccinations against influenza A virus and anti-inflammatory
medications may be one strategy in the treatment of this disease.
Although we observed a significant increase in the number of
influenza A-positive macrophages in PD cases, labeling was also
observed in age-matched control cases. It may be that PD subjects
are somehow more susceptible to the presence of influenza A virus
infection compared to normals. This may be related to genetic
susceptibility in PD that may confer selective vulnerability to
influenza A virus infiltration into the SNpc. Further studies are
required, however, to determine if influenza A directly contributes
to the neuroinflammation and pathology underlying PD, or is
simply coincidental to the disease process.
Materials and Methods
Antibody dilutions
The rabbit BeclinCCP (in house, 1:100). The mouse anti-human
CD14, macrophage marker (1:50), mouse anti-human CD206,
macrophage marker (1:50), mouse anti-human CD3, T-lymphocyte
marker (1:50), mouse anti-human CD4, helper T-lymphocyte
marker (1:50), and mouse anti-human CD8 (1:50), cytotoxic T-
lymphocyte marker were all purchased from BD Pharmingen. The
mouse anti-influenza A virus antibodies, catalogue numbers 35–
481, or 35–483 (1:50), were both purchased from ProSci
Incorporated. The anti-influenza A virus antibodies are known to
recognize the nucleoprotein of numerous strains. Of the two
antibodies, 35–483 gave the most robust degree of staining. The
anti-influenza B virus antibody (1:50) was also from ProSci
Incorporated. To assess apoptosis, the Apoptag peroxidase kit was
employed according the manufacturer’s instructions (Millipore).
Anti-Tyrosine Hydroxylase, clone LNC1 (1:100) was purchased
from Millipore.
Immunohistochemistry
Autopsy brain tissue from seven neuropathologically confirmed
PD cases, five cases from neuropathologically confirmed
dementia with Lewy bodies (DLB), and five neuropathologically
normal cases were studied. Human brain tissue sections used in
this study were provided by the Institute for Memory Impair-
ments and Neurological Disorders at the University of California,
Irvine. Free-floating 40 mm-thick sections were used for immu-
nohistochemical studies as previously described [30]. No approval
from Boise State University Institutional Review Board was
obtained due to the exemption granted that all tissue sections
were fixed and received from University of California, Irvine.
Sections from the substantia nigra were selected for immunohis-
tochemical analysis.
For single labeling, all sections were washed with 0.1 M Tris-
buffered saline (TBS), pH 7.4, and then pretreated with 3%
hydrogen peroxide in 10% methanol to block endogenous
peroxidase activity. Sections were subsequently washed in TBS
with 0.1% Triton X-100 (TBS-A) and then blocked for thirty
minutes in TBS-A with 3% bovine serum albumin (TBS-B).
Sections were further incubated overnight at room temperature in
various primary antibodies as listed above. Following two washes
with TBS-A and a wash in TBS-B, sections were incubated in anti-
rabbit or mouse biotinylated anti-IgG (1 hour) and then in avidin
biotin complex (1 hour) (ABC, Elite Immunoperoxidase, Vector
Laboratories, Burlingame, CA, USA). Antibodies were visualized
using Blue SG substrate (Vector Laboratories). No pretreatment
antigen retrieval protocol was employed for any of the primary
antibodies used in this study. For bright-field immunohistochem-
ical double labeling, primary antibody labeling was detected using
the brown DAB substrate (Vector Labs), while the second label
was visualized using the Blue SG substrate (Vector Labs).
Immunofluorescence Microscopy
Immunofluorescence studies were performed by incubating
sections with primary antibody overnight at a room temperature,
Lewy body (arrow, A). There was a general lack of labeling of both markers in control cases (B). Brown structures (A, B, F, and G) represent
neuromelanin (asterisks), typical of neurons in the SNpc. (C–E): Representative immunofluorescence double labeling employing the BeclinCCP
antibody (red, C) and mAB CD3 (green, D) in the SNpc of a representative PD case, with the overlapped image for both markers (yellow, E). (F and G):
Representative staining in the SNpc of a PD case with anti-CD4 in (F) and anti-CD8 (G), markers for helper T-lymphocytes and cytotoxic
T-lymphocytes, respectively (arrows). (H): Panel H depicts quantitative analysis indicating that approximately 78% of CD3-positive cells co-localized
with the BeclinCCP antibody (p = 7.0861025). Scale bars represent 10 mm.
doi:10.1371/journal.pone.0020495.g004
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followed by secondary anti-rabbit or mouse biotinylated anti-IgG
(1 hour) and then in ABC (1 hour). Visualization was accomplished
by using a tyramide signal amplification kit (Molecular Probes,
Eugene, OR) consisting of Alexa Fluor 488-labeled tyramide (green,
Ex/Em=495/519). For immunofluorescence co-localization stud-
ies, antigen visualization was accomplished using an Alexa fluor
488-labeled tyramide (green, Ex/Em=495/519) for one label and
streptavidin Alexa fluor 555 (red, Ex/Em=555/565) for the second
label, both from Invitrogen (Carlsbad, CA).
Statistical analysis
To determine the percent co-localization, a semi-quantitative
analysis was performed as described previously [11,31,32] by
taking 406 immunofluorescence, overlapping images from three
different fields in the SN in three separate PD cases. Capturing
was accomplished by using a 2.56 photo eyepiece, a Sony high
resolution CCD video camera (XC-77). As an example, to
determine the percent co-localization between CD3 and Be-
clinCCP, photographs were analyzed by counting the number of
CD3-labeled T-lymphocytes alone per 406 field for each case,
and the number of cells labeled with both CD3 and BeclinCCP.
Data are representative of the average number (6S.E.M.) of CD3
or CD3 co-localized with BeclinCCP in each 406 field (3 fields
total for 3 different cases).
Statistical differences in this study were determined using
Student’s two-tailed T-test employing Microsoft Office Excel.
Figure 5. Evidence for influenza A virus on macrophages within the PD brain. (A–C): Representative staining (blue) within the SNpc of the
PD brain utilizing mAB anti-influenza A virus antibody (35–481) depicting staining within large globular cells consistent with a morphology of
macrophages (arrows, A–C). Panel B depicts staining within a macrophage-like cell extending an apparent pseudopod engulfing a smaller circular
structure containing neuromelanin with punctate blue labeling (arrowhead, B). (D): Representative anti-influenza A virus staining (blue) in a control
case identifying a single macrophage-like cell (arrowheads) surrounding a particle of neuromelanin material (arrow). (E): Quantitative analysis of the
number of influenza A-positive macrophages labeled in Ctl (n = 5) or PD cases (n = 4) indicated a significant increase in PD cases (6S.D.,
p-value= 0.01). (F–K): Double labeling immunofluorescence in the SNpc of representative PD cases utilizing mAB anti-CD206, a macrophage marker
(green, F and I), along with anti-influenza A virus labeling (35–481) (red, G and J) with the overlap image (yellow/orange, H and K). Two types of
labeling were observed: In rounder macrophages (F), influenza A staining was more localized and homogenous (G). In perivascular regions,
macrophages were more elongated (I) and influenza A labeling was clearly punctated in appearance (J). (L–N): Identical to Panels F–K, except with
the use of a different antibody marker to both macrophages (CD14, green, L) and influenza A virus (35–483, red, M), with overlap image shown in
Panel N. Punctate labeling of influenza A virus was observed on the surface of macrophages. (O): Control experiment showing lack of influenza A blue
labeling in the absence of primary antibody. (P): Representative staining in a PD case utilizing an antibody against influenza B, indicating a general
lack of blue labeling with this antibody. (Q): Panel Q depicts quantitative analysis indicating that approximately 80% of anti-CD206-positive cells
co-localized with the anti-influenza A virus antibody (p = 4.5561026). Brown structures (A, D, O, and P) represent neuromelanin (asterisks), typical of
neurons in the SNpc. All scale bars are 10 mm.
doi:10.1371/journal.pone.0020495.g005
Figure 6. Influenza A-positive macrophages co-localize with caspase-cleaved Beclin-1 and are surrounded by cytotoxic T-
lymphocytes. Representative immunofluorescence triple labeling in a PD case was undertaken using three different antibodies: (A) anti-influenza A
(red), (B) BeclinCCP (blue), and (C) anti-CD8 (green). (D): Panel D displays the overlapped image for all three antibodies indicating the presence of
influenza A viral proteins on an apparent macrophage displaying diffuse BeclinCCP labeling (arrow, D). In addition, numerous CD8+ cells are in close
proximity to the macrophage and some of these cells demonstrated colocalization with the influenza A virus antibody (arrowheads, D). All scale bars
are 10 mm.
doi:10.1371/journal.pone.0020495.g006
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Supporting Information
Figure S1 Representative pathology in PD cases. Panels
A, C, and E depict images from representative PD cases, while
Panels B, D, and F are from representative control cases. (A and
B): The presence of Lewy bodies (arrows, A) and Lewy neurites in
PD (arrowheads, A) that was absent in age-matched control
sections (B). (C and D): Neuroinflammation in PD cases was
revealed following the demonstration of massive gliosis that was
absent in age-matched control cases (D). (E and F): Loss of
dopaminergic neurons in PD cases was revealed following labeling
with an anti-tyrosine hydroxylase antibody (E) compared to age-
matched controls (F). Note also the general loss of pigmentation in
PD cases (A and E). All antibody staining is shown in blue, while
brown labeling depicts the presence of neuromelanin that is typical
of neurons found in the SNpc. All scale bars represent 10 mm.
(DOC)
Figure S2 Relative lack of oligodendrocyte labeling in
the SNpc of PD. Representation from a PD case in blue showing
the relative lack of labeling using anti-Olig1 in the SNpc (B) as
compared to the widespread staining observed utilizing the
BeclinCCP antibody (A). Arrows in Panel B designate the few
oligodendrocytes labeled by anti-Olig1 in the SNpc. Brown
structures shown in Panels A and B represent neuromelanin,
typical of neurons in the SNpc. Scale bars represent 10 mm.
(DOC)
Figure S3 Evidence for influenza A virus on macro-
phages within the DLB brain. Double-labeling immunoflu-
orescence in the SNpc of a representative DLB case utilizing mAB
anti-CD206, a macrophage marker (green, A) along with anti-
influenza A virus labeling (35–481) (red, B) with the overlap image
(yellow/orange, C). Scale bar represents 10 mm.
(DOC)
Table S1
(DOC)
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